hct
recipi
virolog
proven
influenza
infect
januari
octob
store
serum
plasma
sampl
access
includ
studi
weekli
plasma
serum
sampl
collect
within
week
diagnosi
lower
respiratori
tract
diseas
lrd
case
upper
respiratori
tract
diseas
urd
alon
within
week
diagnosi
urd
test
presenc
influenza
viru
rna
realtim
reversetranscriptionpolymeras
chain
reaction
rtpcr
clinic
data
collect
databas
supplement
chart
review
studi
approv
institut
review
board
fred
hutchinson
cancer
research
center
fhcrc
subject
sign
inform
consent
permit
use
data
store
sampl
research
patient
nasal
wash
andor
bronchoalveolar
lavag
sampl
posit
influenza
b
specif
influenza
subtyp
realtim
rtpcr
assay
serum
plasma
frozen
test
realtim
rtpcr
assay
target
influenza
matrix
gene
previous
describ
limit
detect
copiesml
specimen
posit
result
less
copiesreact
repeat
confirm
posit
influenza
urd
lrd
defin
describ
day
influenza
diagnosi
defin
day
sampl
first
posit
virolog
test
follow
hct
lymphopenia
steroid
use
analyz
describ
presenc
coinfect
defin
detect
pathogen
bacterium
mold
opportunist
viru
respiratori
site
andor
blood
obtain
within
week
influenza
viru
isol
hypoxemia
defin
ambient
air
oxygen
satur
need
oxygen
supplement
respiratori
failur
defin
respiratori
distress
condit
requir
mechan
ventil
assist
bilevel
posit
airway
pressur
continu
posit
airway
pressur
intub
occur
day
influenza
diagnosi
death
consid
relat
influenza
patient
die
respiratori
failur
influenza
viru
consid
contributor
lung
injuri
conduct
analys
first
character
occurr
rna
detect
blood
evalu
possibl
risk
factor
occurr
second
determin
overal
correl
detect
influenza
viral
rna
blood
clinic
outcom
among
entir
cohort
hct
recipi
laboratoryconfirm
influenza
infect
n
clinic
outcom
test
includ
lrd
hypoxemia
respiratori
failur
time
death
caus
time
influenzaassoci
death
third
among
patient
influenza
urd
present
n
presenc
influenza
rna
urd
present
evalu
analyz
timedepend
risk
factor
progress
lrd
final
among
patient
influenza
lrd
present
follow
progress
n
influenza
rna
detect
blood
analyz
risk
factor
lrd
outcom
influenzaassoci
death
death
caus
statist
analys
perform
sa
version
sa
institut
inc
cari
nc
outcom
preval
rate
high
enough
odd
ratio
would
afford
good
approxim
rel
risk
rr
util
univari
bivari
poisson
regress
model
robust
varianc
directli
estim
rr
confid
interv
ci
lrd
hypoxemia
respiratori
failur
univari
bivari
cox
proport
hazard
model
use
evalu
adjust
hazard
ratio
hr
mortal
progress
lrd
bivari
model
util
candid
confound
plu
viremia
number
event
low
full
multivari
model
could
fit
januari
octob
blood
specimen
patient
lrd
patient
urd
avail
tabl
account
approxim
overal
number
patient
virologicallyproven
influenza
time
period
fhcrc
characterist
cohort
repres
entir
cohort
total
blood
sampl
serum
sampl
plasma
sampl
test
presenc
influenza
viral
rna
averag
sampl
per
patient
test
rang
median
interv
day
demograph
characterist
patient
list
tabl
precis
data
initi
antivir
drug
avail
patient
antivir
treatment
administ
patient
diagnosi
influenza
earli
antivir
treatment
urd
within
hour
sampl
acquisit
virolog
test
achiev
patient
overal
influenza
viral
rna
detect
patient
frequent
observ
patient
lrd
patient
urd
vs
p
fisher
exact
test
detect
rate
similar
across
time
p
signific
supplement
figur
patient
lrd
viral
rna
blood
influenza
urd
initi
present
progress
lrd
rna
detect
median
day
rang
day
lrd
diagnosi
median
maximum
rna
load
among
posit
result
copiesml
rang
copiesml
differ
urd
lrd
cohort
durat
rna
detect
blood
median
week
rang
week
influenza
viral
rna
detect
occur
patient
profound
lymphopenia
compar
patient
without
lymphopenia
rr
ci
p
three
patient
viral
rna
blood
compar
patient
season
influenza
b
rr
ci
p
rna
viremia
also
less
common
patient
urd
patient
lrd
rr
ci
p
bivari
analys
detect
influenza
remain
statist
signific
lymphopenia
time
antivir
treatment
ad
model
adjust
rr
ci
p
lymphopenia
adjust
rr
ci
p
earli
vs
late
antivir
treatment
significantli
wors
clinic
outcom
observ
patient
rna
detect
blood
compar
without
rna
blood
tabl
patient
viremia
lymphopen
progress
occur
set
lymphopenia
subgroup
analysi
n
patient
lymphopenia
perform
tabl
adjust
lymphopenia
time
initi
antivir
treatment
intens
condit
regimen
influenza
viru
type
b
vs
separ
bivari
model
associ
viremia
remain
statist
signific
adjust
hr
rang
influenza
rna
detect
blood
posit
neg
predict
valu
lrd
respect
sensit
specif
respect
patient
n
analysi
restrict
patient
present
urd
n
similar
valu
found
respect
presenc
rna
detect
blood
time
diagnosi
lrd
associ
higher
probabl
death
supplement
figur
cox
proport
hazard
analysi
show
influenza
viral
rna
detect
blood
associ
higher
risk
overal
influenzaassoci
death
tabl
none
candid
variabl
lymphopenia
corticosteroid
influenza
strain
presenc
invas
coinfect
intens
condit
regimen
statist
significantli
associ
hypoxemia
mechan
ventil
overal
influenzarel
death
first
studi
systemat
assess
frequenc
time
pattern
influenza
viral
rna
detect
blood
use
quantit
rtpcr
among
hct
recipi
proven
influenza
diseas
although
signific
viral
rna
detect
blood
like
differ
viru
detect
viral
rna
pcr
necessarili
prove
presenc
replic
viru
viral
nucleic
acid
detect
blood
associ
diseas
sever
rna
dna
virus
cytomegaloviru
adenoviru
sever
acut
respiratori
syndrom
coronaviru
avian
influenza
longitudin
studi
viral
rna
detect
blood
occur
approxim
patient
influenza
patient
influenza
lrd
viral
rna
blood
detect
day
prior
diagnosi
lrd
risk
factor
progress
urd
lrd
among
patient
present
urd
influenza
viral
rna
blood
associ
hypoxemia
respiratori
failur
overal
influenzarel
death
furthermor
influenza
rna
detect
blood
associ
increas
mortal
among
patient
influenza
lrd
although
sever
report
influenza
rna
detect
blood
incid
viru
isol
viral
rna
detect
blood
thought
low
particularli
season
influenza
howev
influenza
infect
infect
newli
circul
pandem
virus
may
like
caus
virem
phase
circul
season
human
influenza
virus
limit
studi
includ
retrospect
natur
analysi
rel
small
number
patient
influenza
miss
donor
recipi
vaccin
statu
miss
weekli
sampl
patient
made
exact
time
pattern
rna
detect
rel
influenza
urd
lrd
difficult
assess
rel
small
sampl
size
prevent
us
perform
model
includ
possibl
risk
factor
simultan
form
sever
differ
bivari
model
adjust
import
factor
eg
earli
initi
antivir
therapi
hour
model
show
viremia
signific
factor
clinic
import
outcom
tabl
analyz
preemptiv
antivir
therapi
possibl
factor
outcom
base
previou
studi
antivir
therapi
consist
larg
oseltamivir
earlier
case
influenza
treat
final
use
plasma
serum
sampl
quantit
rtpcr
could
test
cultur
cellular
compon
due
retrospect
natur
studi
optim
blood
compon
influenza
rna
detect
defin
although
serum
plasma
sampl
studi
collect
specif
futur
rna
detect
influenza
rna
detect
rate
declin
older
sampl
sampl
evenli
spread
throughout
studi
period
nevertheless
recogn
possibl
use
serum
plasma
store
mani
year
may
underestim
true
rate
influenza
rna
may
introduc
bia
conclus
detect
viral
rna
blood
risk
factor
progress
urd
lrd
hct
recipi
urd
present
especi
lymphopenia
viremia
also
appear
associ
mortal
among
patient
influenza
lrd
thu
influenza
rna
detect
blood
may
serv
marker
poor
overal
outcom
immunosuppress
patient
futur
studi
confirm
find
larger
cohort
focu
defin
optim
blood
fraction
contain
highest
amount
viru
investig
use
viral
rna
detect
blood
marker
progress
diseas
set
influenza
diseas
